[A26-34] Elinzanetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2026
Project no.:
A26-34
Commission:
Commission awarded on 31.03.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Patients with moderate to severe vasomotor symptoms associated with the menopause
- Patients for whom hormone replacement therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: added benefit not proven
- Patients for whom hormone replacement therapy is not an option or who have decided against hormone replacement therapy after an individual risk-benefit assessment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A26-34
| Project no. | Title | Status |
|---|---|---|
| A26-35 | Elinzanetant (vasomotor symptoms associated with breast cancer treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A26-101 | Elinzanetant (vasomotor symptoms in menopause) – Addendum to Project A26-34 | Commission completed |
Federal Joint Committee (GBA)
01-10-2026 A G-BA decision was published.
GBA documents on this decision